Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

BIO-BUZZ: Novel Biotherapeutic Approaches to Treating Cancer

August 11th 2010

Novel therapeutic approaches represent the latest advances in targeted cancer therapy that may one day provide clinicians with a better means of custom-tailoring cancer treatment. Eventually, treatments may be individualized based on unique sets of molecular targets.

The Academy: June 2007

July 15th 2010

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther toward knowledge and discovery. In this issue: 1) University of Texas M.D. Anderson Cancer Center, Houston, TX: Assessment Model for Lung Cancer Risk 2) Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA: Diabetes Drug Boosts Efficacy of Platinum Chemotherapy Agents, and more

The Rapid Reporter: June 2007

July 14th 2010

This issue features reports from: American Association for Cancer Research meeting April 14-18, 2007 Los Angeles, CA BIO International Convention May 6-9, 2007 Boston, MA

Reimbursement and Managed Care News: June 2007

July 14th 2010

Topics covered in this issue include: 1) High Cancer Drug Costs Altering the Research and Treatment Dynamic 2) $128 Million Settlement to Physicians 3) Coinsurance Change for Medicare Beneficiaries for Colon Cancer Screening, and more

Physicians' Financial News for June 2007

July 14th 2010

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Cell Therapeutics' Indolent NHL Agent Gets Fast Tracked 2) First Low-Molecular-Weight Heparin Approved for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer, and more

The Virtual Window: Clinical Trial Reports--June 2007

July 14th 2010

The Clinical Trials reported in this issue are: PHASE I: CuraGen, TopoTarget Begin Study of HDAC Inhibitor Candidate as Combination Therapy for Soft Tissue Sarcomas Ambrilia%u2019s Therapeutic Peptide Shows Clinical Activity in Metastatic Prostate Cancer Patients PHASE II: Alchemia%u2019s Precursory Evaluation of mCRC Study Presents Positive Efficacy Data IsoRay%u2019s Cesium-131 Established as Front-Line Treatment for Early-Stage Prostate Cancer, and more

Clinical Abstracts from Overseas: June 2007

July 14th 2010

Articles in this issue include: 1) Norway: Hopes for Trastuzamab Use in Endometrial Cancer 2) Switzerland: New Guidelines Highlight Use of Bisphosphonates in Elderly Patients With Bone Metastases 3) Italy: Bringing Out All of the Artillery to Fight Mesothelioma, and more

News Reports: June 2007

July 14th 2010

The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women, and more

HRT Linked with Breast and Ovarian Cancers

July 12th 2010

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

AUA Updates Prostate Cancer Guidelines

July 12th 2010

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.

The Importance of Biotechnology

July 12th 2010

With so many developments in the biotechnology industry, keeping up-to-date is more important than ever. Oncology & Biotech News is dedicated to helping practicing oncologists stay current on the latest therapeutic breakthroughs.

The Academy: September 2007

July 12th 2010

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther in pursuit of knowledge and discovery. In this issue: 1) University of Michigan Comprehensive Cancer Center, Ann Arbor, MI: Gene Fusions Switch on Prostate Cancer 2) Dana-Farber Cancer Institute in Boston, MA: New, Powerful Lung Tumor Suppressor Gene Found, and more

Reimbursement and Managed Care News: September 2007

July 12th 2010

The topics covered in this issue include: 1) Exemestane Is a Cost-Effective Alternative to Tamoxifen in Estrogen Receptor%u2013Positive Breast Cancer 2) A More Accurate Way of Deciding Which Prostate Cancers to Treat? 3) Senate Proposal Would Increase Payments to Oncologists%u2026 and more

The Rapid Reporter: American Society of Clinical Oncology

July 12th 2010

Two presentations are highlighted from the meeting of the American Society of Clinical Oncology held in Chicago, IL: 1) Navigating Multiple Pathways: Evolving Strategies and Future Directions in Targeted Therapies 2) Two Studies Evaluate Efficacy and Safety of Lapatinib (Tykerb) in Advanced Breast Cancer

Physicians' Financial News for September 2007

July 12th 2010

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) Amgen: Amgen Oncology Under Review 2) Myriad Genetics, Inc.: Launches Test to Predict Toxicity to 5-FU 3) GPC Biotech AG: Pulls NDA for Prostate Cancer Drug, and more

Clinical Trial Reports: September 2007

July 8th 2010

The Clinical Trials reported in this issue include: PHASE IV: Obesity a Major Risk Factor for Multiple Myeloma PHASE III: 1) Long-Term Safety of Adjuvant Trastuzumab (Herceptin) 2) Bevacizumab (Avastin) Helps Slow Tumor Growth in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer 3) Addition of Bevacizumab To Interferon Alfa 2a Nearly Doubles Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer, and more

Clinical Abstracts from Overseas: September 2007

July 8th 2010

Articles in this issue include: 1) England: GAMEC for Untreated or Relapsed Refractory Germ-Cell Tumors Preventing Oxaliplatin-Induced Peripheral Neuropathy 2) Australia: Immunodeficiency May Be Linked to Multiple Cancer Types 3) Sweden: Long-Term Steroid Use in Rheumatoid Arthritis Has One Benefit, at Least 4) Netherlands: Increasing Survival of Infants With Acute Lymphoblastic Leukemia, and more

Five-year Follow-Up of 300 Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy of CLL

July 8th 2010

Final results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.

Active Symptom Control With or Without Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

July 8th 2010

Chemotherapy is widely used in the treatment of malignant mesothelioma, but it has never been compared in a randomized trial with active symptom control (ASC) alone.

"Longboat" Delivery May Invade Tumor Cells and Deliver Chemotherapy

July 8th 2010

Like the Vikings of old, scientists are hoping a new "longboat" drug delivery system will compromise the walls of resistant cancer cells and fight them with high-dose chemotherapy released only when they are inside.